This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at [email protected] or call + 1 (702) 988 2320.
Stem cell therapy has become a very promising and advanced scientific research area in recent years. Human stem cells are unspecialized cells that can be found throughout the body. They have the potential to differentiate into any cell in an organism and to self-renew. Stem cells can be found in both embryonic and adult cells. Personalized medicine is a cutting-edge approach to disease prevention and treatment that considers individual variances in drug response. Stem cell therapy is a promising treatment that can be adapted to a patient's specific needs as well as their ailment. Stem cell therapy has the potential to provide a futuristic personalized “medication” in the event of tissue damage caused by surgeries, toxins, trauma, ageing, pharmaceutical complications, autoimmune disorders, and a variety of other conditions that are now unaddressed by current medicine.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain